Enhanced NK activity during blast crisis in chronic myelogenous leukemia (CML)

Delwail, Vincent; Meseri, A.; Brizard, A.; Lecron, Jean‐Claude; Sadoun, A.; Costerousse, Fabienne; Guilhot, Joëlle; Tanzer, J; Laforest, P. Goube de

doi:10.1016/0145-2126(92)90024-2

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More recent studies have shown that CML patients who respond to interferon [56] or other immune modulatory therapies such as heat shock protein vaccination generally have higher CD56+, CD16+ NK cell mediated cytotoxic activity towards K562 cells as compared to treatment non-responders [57]. An interesting observation is that as a last-ditch effort by the immune system to preserve the host, NK cell activity in blast crisis phase of CML is reported to be increased in comparison to healthy controls [58]. A practical explanation may be that the high concentrations of circulating NK activatory compounds may be systemically activating the NK cells.…”

Section: Immunogenicity Of Cml: the Innate Immune Responsementioning

confidence: 99%

Therapeutic use of Aldara™ in chronic myeloid leukemia

Marleau¹,

Lipton

Riordan³

et al. 2007

J Transl Med

View full text Add to dashboard Cite

The potent clinical responses seen in patients with chronic myeloid leukemia (CML) after administration of donor-specific lymphocytes, as well as the correlation between the presence of antigen specific T cells and prolonged remission in these patients, suggests a role for the immunological control of CML. Here we propose Aldara™, a clinically used formulation of imiquimod, as an agent for augmenting immune responses to CML antigens. Our proposition is based upon 3 tenets: 1) Endogenous dendritic cells (DC) of CML patients, which are known to be derived from the malignant clone, express and present various leukemic antigens; 2) CML-antigen reactive T cell clones exist in the patient but in many situations are ineffectively stimulated to cause significant hematological responses; and 3) Antigen presentation by mature, activated DC, which endogenously express CML-antigens may endow the pre-existing ineffective T cell responses with ability to control CML progression. The practical use of Aldara™ as a localized activator of DC in the context of present day leukemic therapeutics, as well as various properties of this unique immune modulator will be discussed.

show abstract

Section: Immunogenicity Of Cml: the Innate Immune Responsementioning

confidence: 99%